Biohaven Ltd. (BHVN) FinancialsBHVNBiohaven Ltd.

Evaluating the bottom line, Biohaven Ltd. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -799.46%, provide a clear picture of how effectively BHVN converts its operational activities into shareholder value.

In the context of the broader market, BHVN competes directly with industry leaders such as GPCR and ZYME. With a market capitalization of $1.80B, it holds a leading position in the sector. When comparing efficiency, BHVN's gross margin of N/A stands against GPCR's N/A and ZYME's 100.00%. Such benchmarking helps identify whether Biohaven Ltd. is trading at a premium or discount relative to its financial performance.

Biohaven has consistently reported negative net income, with Q2 2026 showing a net loss of $137.31 million. The forward P/E ratio is 0, indicating no expected earnings growth, and the debt-to-equity ratio has surged to 2123.06%, raising concerns about financial stability.